Calprotectin News

The Workflow Revolution Continues for Serum Calprotectin

Following on from the success of the fCAL® turbo and the fPELA® assays, BÜHLMANN has now launched the sCAL® turbo for serum calprotectin, that operates on the same principles as its predecessors. The BÜHLMANN sCAL® turbo runs on the mainstream clinical chemistry analysers and the time to first result is 10 minutes, with further results

Continue Reading

New Presentation Format for UK NEQAS

BÜHLMANN has been the market leading provider of faecal calprotectin assays in the UK for over 10 years, holding a significant portion of the market share, as recorded on the National External Quality Assurance Scheme (NEQAS). The BÜHLMANN results are split across the two main laboratory assays: fCAL ELISA and fCAL turbo assays. There is

Continue Reading

Point-of-Care Calprotectin Testing Just Got Easier with New and Improved Quantum Blue® III

To better support timely diagnosis, monitoring and treatment optimisation for IBD patients, the newly improved BÜHLMANN Quantum Blue® III reader and tests are the perfect in-clinic solution. Available exclusively in the UK from Alpha Laboratories Ltd., the calprotectin experts, the system offers simple, rapid lateral flow test technology, with full quantitation and LIMS data connectivity.

Continue Reading

New App Helps Bowel Disease Patients Monitor Their Own Treatment

This article from the Mid and South Essex NHS Foundation Trust discusses the recent implementation of the BÜHLMANN IBDoc® Calprotectin Home Test within their Trust. You can also read about this implementation in our latest issue of Perspective. We talked to some of the key team members about their focus on introducing new technologies to

Continue Reading

Faecal Calprotectin Indicates Intestinal Inflammation in COVID-19

In this pilot study, a relation between GI symptoms, intestinal inflammation (determined by FC) and faecal SARS-CoV-2-RNA in hospitalised patients with COVID-19 who did not require intensive care measures was explored. Click here to visit the BMJ website to find out more about the study and its results.

Continue Reading
IBD Monitoring

Calprotectin is Now Part of the New ECCO & ESGAR Guidelines

Faecal calprotectin (FC) is now part of the new official European Crohn’s and Colitis Organisation (ECCO) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) guidelines.

Continue Reading

The New Faecal Calprotectin Care Pathway | NICE

The New Faecal Calprotectin Care Pathway, developed by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust, and implemented by the Yorkshire and Humber AHSN, supports the implementation of NICE guidance DG11, for the detection of inflammation in the bowel (i.e. IBS vs IBD). The innovative and sensitive pathway based will help

Continue Reading

Three Simple Tests Could Save the NHS at least £6.9 Billion

A report from BIVDA and Innovate UK has identified that wider use of some IVD tests could save money and improve patient care. As we celebrate the 70th anniversary of the NHS is this one way to strengthen its future? Calprotectin is one of the tests identified in the report. It is already utilised in the NHS,

Continue Reading
Calprotectin Goes Mobile

Big Changes Coming Soon to a Clinic Near You

Calprotectin Testing Goes Mobile With advances in technology and the ubiquitous use of mobile devices, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to

Continue Reading

NICE releases Medtech Innovation Briefing on calprotectin point of care and home testing for monitoring IBD treatment.

On 4th December 2017 the National Institute for Health and Care Excellence issued a Medtech Innovation Briefing [MIB132]: ‘Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease’. This describes the innovative aspect that test results can be acted on more quickly than waiting for standard laboratory tests and could help reduce colonoscopies and clinical appointments. Costs may

Continue Reading